A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines

[1]  D. Gerhard,et al.  MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Imbeaud,et al.  Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer , 2017, Cancers.

[3]  M. Berger,et al.  A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers , 2017, Clinical Cancer Research.

[4]  Jun Gong,et al.  Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[6]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Yusuke Nakamura,et al.  FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib , 2016, Cancer science.

[8]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[9]  C. Rudin,et al.  Missing the mark in FGFR1‐amplified squamous cell cancer of the lung , 2016, Cancer.

[10]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Ishikawa,et al.  MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment , 2016, Journal of clinical medicine.

[12]  A. Adjei,et al.  FGFR Signaling as a Target for Lung Cancer Therapy , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  A. Chella,et al.  microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers , 2015, Proceedings of the National Academy of Sciences.

[14]  P. Morin,et al.  Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients , 2015, Journal of clinical medicine.

[15]  D. Beer,et al.  A Novel Serum 4-microRNA Signature for Lung Cancer Detection , 2015, Scientific Reports.

[16]  F. Hirsch,et al.  MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type , 2014, Oncotarget.

[17]  P. Bunn,et al.  FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies , 2014, Clinical Cancer Research.

[18]  F. Boccardo,et al.  Role of microRNAs in malignant mesothelioma , 2014, Cellular and Molecular Life Sciences.

[19]  D. Beer,et al.  Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[20]  L. Sequist,et al.  Genetic Changes in Squamous Cell Lung Cancer: A Review , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[22]  J. Balko,et al.  A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT , 2011, British Journal of Cancer.

[23]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[24]  P. Bunn,et al.  Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells , 2009, Molecular Pharmacology.

[25]  Kenichi Sugihara,et al.  Clinical Significance of High Mobility Group A2 in Human Gastric Cancer and Its Relationship to let-7 MicroRNA Family , 2008, Clinical Cancer Research.

[26]  J. Melamed,et al.  Antiproliferative Effects by Let-7 Repression of High-Mobility Group A2 in Uterine Leiomyoma , 2008, Molecular Cancer Research.

[27]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[28]  T. Jiang,et al.  FGFR1 amplification in lung squamous cell carcinoma: a systematic review with meta-analysis. , 2015, Lung cancer.

[29]  David P. Bartel,et al.  Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation , 2022 .